Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with Type 2 diabetes mellitus.

Yoko Koike,Shin-Ichiro Shirabe,Hajime Maeda, Ayako Yoshimoto,Keiko Arai,Atsushi Kumakura,Koichi Hirao,Yasuo Terauchi

Diabetes Research and Clinical Practice（2019）

引用 29|浏览5

暂无评分

摘要

•Canagliflozin, an SGLT2 inhibitor, decreased both blood glucose and body fat.•Improvement of insulin resistance was demonstrated using euglycemic hyperinsulinemic clamp study.•Reduction of visceral fat and ectopic fat is considered to be important.•SGLT2 inhibitors are useful therapeutic agent for Japanese T2DM patients.

查看译文

关键词

Canagliflozin,SGLT2,Type 2 diabetes,Insulin resistance,Glucose clamp,Visceral fat

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要